GYRE
Gyre Therapeutics, Inc.
GYRE trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over GYRE overall, supported by stronger fundamentals and lower modeled downside.
GYRE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
GYRE's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GYRE PE Valuation
GYRE has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GYRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect GYRE's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over GYRE on the outlook, with more favorable earnings and revenue expectations.
GYRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $0.05 | +$2.86 |
| Q3 2024 | -$1.26 | +$19.44 |
| Q2 2024 | -$1.87 | +$20.63 |
| Q1 2024 | -$2.93 | -193% |
| Q4 2023 | -$2.81 | +$1.09 |
| Q3 2023 | -$20.70 | -463% |
| Q2 2023 | -$22.50 | -$18.60 |
| Q1 2023 | $3.15 | +$41.25 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 114% for GYRE versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
GYRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $32.9M | +7.8% |
| Q2 2026 | $29.1M | +8.7% |
| Q1 2026 | $22.5M | +2.1% |
| Q4 2025 | $37.2M | +33% |
| Q3 2025 | $30.6M | +20% |
| Q2 2025 | $26.8M | +6.1% |
| Q1 2025 | $22.1M | -19% |
| Q1 2022 | $794K | -46% |
GYRE's revenue has grown year over year for six quarters in a row: $33M last quarter, up 7.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | -27 points |
| Q2 2026 | -49% | -58 points |
| Q1 2026 | -42% | -52 points |
| Q4 2025 | 0.3% | -1.8 points |
| Q3 2025 | 23% | +6.1 points |
| Q2 2025 | 8.1% | -4.8 points |
| Q1 2025 | 10% | -19 points |
| Q4 2024 | 2.1% | N/A |
GYRE's operating margin was −4.6% last quarter, down 27 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GYRE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GYRE on profitability, with a higher operating margin.
GYRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | -224% |
| Q2 2026 | -$17M | -1027% |
| Q1 2026 | $3M | +$3.3M |
| Q4 2025 | -$5.8M | -$3.1M |
| Q3 2025 | $4M | +288% |
| Q2 2025 | $1.8M | +$8.8M |
| Q1 2025 | -$251K | -109% |
| Q3 2024 | $1M | +$4.3M |
GYRE has burned cash in most quarters: −$25M over the past year, against $3M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GYRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GYRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +5.7M shares |
| 1 year | +2.2% | +2.3M shares |
| 3 years | +4955% | +104M shares |
| 5 years | +7124% | +105M shares |
GYRE has 106M diluted shares, up 2.2% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GYRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GYRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -15.1x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -2.8x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
| Q1 2023 | -1.3x | Net Cash |
| Q3 2022 | -2.0x | Net Cash |
GYRE has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GYRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 10.3 | Oversold |
GYRE's weekly RSI is 32 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GYRE PE vs Healthcare Sector
| Metric | GYRE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GYRE has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GYRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.88 | 27% below |
| 20 week MA | $6.33 | 32% below |
| 50 week MA | $6.89 | 38% below |
| 100 week MA | $7.91 | 46% below |
| 200 week MA | $9.42 | 54% below |
GYRE is in a downtrend: it's below all five of its weekly moving averages, and 54% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GYRE on trend strength, trading above more of its moving averages.
GYRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $101.4 | $97.1 | -4.3% |
| 2021 | $97.1 | $15.9 | -84% |
| 2022 | $15.9 | $7.50 | -53% |
| 2023 | $7.50 | $25.7 | +243% |
| 2024 | $25.7 | $12.5 | -52% |
| 2025 | $12.5 | $7.26 | -42% |
| 2026 YTD | $7.26 | $4.30 | -41% |
GYRE's yearly returns have swung widely, from +243% in 2023 to −84% in 2021. It's down 41% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GYRE on returns for 2026, with the stronger performance.